Immunomedics (IMMU) Stock Price, News & Analysis

Company Overview

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Key Stats

• Today's Range: $87.86 to $87.86
• 50-Day Range: $85.08 to $87.86
• 52-Week Range: $8.80 to $87.93
• Volume: N/A
• Average Volume: 4.01 million shs
• Market Capitalization: $20.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMMU Stock Analysis - Frequently Asked Questions

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.39. The biopharmaceutical company had revenue of $20.07 million for the quarter, compared to analyst estimates of $24.81 million.

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Gilead Sciences (GILD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/05/2020
• Today: 3/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic Substances
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMMU
• CIK: 722830
• Web: www.immunomedics.com
• Phone: 973-605-8200
• Fax: N/A
• Employees: 366
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-357,190,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -132.40%
• Return on Assets: -51.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.84
• Quick Ratio: 12.58

Sales & Book Value

• Annual Sales: $290,000.00
• Price / Sales: 70,028.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.38 per share
• Price / Book: 63.67

Miscellaneous

• Outstanding Shares: 231,144,000
• Free Float: N/A
• Market Cap: $20.31 billion
• Optionable: Optionable
• Beta: 2.90